5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): an effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study

Cancer. 1983 Jul 15;52(2):193-7. doi: 10.1002/1097-0142(19830715)52:2<193::aid-cncr2820520202>3.0.co;2-s.

Abstract

One hundred and thirty-one patients (118 evaluable) with disseminated breast cancer were treated with a combination of 5-fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM). The objective response rate for 82 evaluable patients whose disease was refractory to previous CMF or L-PAM chemotherapy was 35%; that for 36 evaluable patients who had not previously received chemotherapy, 56%. The hematologic toxicity of this therapy was generally mild and acceptable. It is believed that FOAM is an effective therapy for patients whose tumors are resistant to CMF.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols*
  • Breast Neoplasms / drug therapy*
  • Clinical Trials as Topic
  • Doxorubicin / administration & dosage
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Leukocyte Count
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage
  • Platelet Count
  • Prognosis
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents
  • Mitomycins
  • Mitomycin
  • Vincristine
  • Doxorubicin
  • Fluorouracil

Supplementary concepts

  • FOAM protocol